We review the immune-related hurdles in mRNA-based non-immunogenic applications.

We suggest some methods to reduce unwanted innate immune responses.

Small-molecule immune inhibitors might advance non-immunogenic mRNA strategies.

Simultaneous inhibition on different levels of the pathways should be considered.

Improvements will be required in mRNA delivery to ensure longer protein expression.